BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2230926
,
PTEN
,
cell-cell adhesion
,
Ischemia
,
Leukocyte
,
Personalized medicine
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
JAK2
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Basophil of peripheral blood
Neutrophil of bone marrow
Eosinophil of peripheral blood
Leukocyte (polymorphonuclear) of peripheral blood
Myeloid cells of peripheral blood
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.
TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to …
Identification and validation of the association of Janus kinase 2 mutations with the response to im…
Myeloid sarcoma in JAK2-positive myelodysplastic neoplasms with fibrosis: a case report and literatu…
JAK2-mediated Intracellular Signaling.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Anticoagulation in Gastroesophageal Varices and JAK2 Mutation
JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis
Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ